View Single Post
Old 03-22-2019, 11:45 AM   Nav to Top 
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 251
Favorites: Aapl celg onxx
Rep Power: 106
Reputation: 36
Biohero is on a distinguished road
Default CPH.T (MC $39 M) Profitable Biotech / 2x Big Drug approvals this year

Undiscovered and Profitable Biotech with significant upside potential ..Many new attractive Product launches and approvals expected within this year .Tgt $10+


Cipher Pharmaceuticals (CPH.T)

Market Cap: $39.7 Million CAD
Cash $10.4 Million CAD
Price: $1.46

Shares Out: 26.8 Million


Slide Presentation
https://filecache.investorroom.com/m...19%20Final.pdf


Cipher anticipates several key milestones in 2019 that will continue to enhance long term value, including:

Xydalba launch in first half of 2019

DTR-001 pre-clinical results in Q2 2019

Regulatory approval for plecanatide from Health Canada in Q4 2019

Regulatory approval for A-101 from Health Canada in Q4 2019

Top line results for MOB-015 Phase 3 study in North America expected in late Q4 2019


Largest Shareholder :

John Douglas Mull, MD 9,911,265
Grandeur Peak Global Advisors LLC 1,522,200
Taylor Asset Management, Inc. (Canada) 243,100
Harold Morton Wolkin, CFA 184,134
Arthur M. Deboeck 104,300
Mark A. Beaudet 87,790
Christian Godin 39,009
Robert D. Tessarolo 37,013
Stephen L. Lemieux, CPA 25,008
Acadian Asset Management LLC 9,093


Biohero is offline   Rate this post Yes | No Reply With Quote